Scarica l'app Stockscreener
48.17
6.41%
2.90
Dopo l'orario di chiusura:
48.02
-0.15
-0.31%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PTCT Giù?
Forum
Previsione
Ptc Therapeutics Inc Borsa (PTCT) Ultime notizie
Phenylketonuria Market to Witness Promising Upswing by 2034, - openPR.com
PTC Therapeutics (PTCT) Is Down 11.4% After Q2 Net Loss Narrows but Six-Month Turnaround Surprises - simplywall.st
PTC Therapeutics (NASDAQ:PTCT) Shares Gap DownShould You Sell? - MarketBeat
What makes PTC Therapeutics Inc. stock price move sharplyROI Verified Swing Candidates - sisain.net
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q2 2025 Earnings Call Transcript - Insider Monkey
PTC Therapeutics (NASDAQ:PTCT) Given New $79.00 Price Target at Wells Fargo & Company - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Cut to Hold at Wall Street Zen - MarketBeat
FY2025 Earnings Estimate for PTCT Issued By Leerink Partnrs - MarketBeat
Phenylketonuria Market to Witness Promising Upswing by 2034, DelveInsight Forecasts | PTC Therapeutics, Homology Medicine, Synlogic, BioMarin Pharma - Barchart.com
Earnings Update: PTC Therapeutics, Inc. (NASDAQ:PTCT) Just Reported Its Second-Quarter Results And Analysts Are Updating Their Forecasts - Yahoo Finance
Momentum Screeners Rank PTC Therapeutics Inc. in Top 5 TodayCommunity Strategy With High Win Rate Backtested - metal.it
PTC Therapeutics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
PTC Therapeutics, Inc. (NASDAQ:PTCT) CEO Matthew B. Klein Sells 10,739 Shares - MarketBeat
PTC Therapeutics: Pioneering a New Growth Cycle in Rare Disease Innovation - AInvest
PTC Therapeutics and the Launch of Sephience™: A Catalyst-Driven Play in Rare Disease Innovation - AInvest
PTC Therapeutics Enters Rights Satisfaction Agreement - The Globe and Mail
PTC Therapeutics Announces Q2 2025 Financial Results - The Globe and Mail
PTC Therapeutics outlines Sephience $1B-plus U.S. revenue potential following FDA and EU launches - MSN
Federated Hermes Inc. Grows Stock Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics Beat Expectations But Shares Still Dropped - Finimize
PTC Therapeutics price target lowered to $70 from $72 at Baird - TipRanks
Transcript : PTC Therapeutics, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
PTC Therapeutics stock price target raised to $63 from $60 at RBC Capital - Investing.com Canada
PTC Therapeutics stock price target raised to $56 from $52 at TD Cowen - Investing.com Canada
RBC Raises Price Target on PTC Therapeutics to $63 From $60, Keeps Outperform Rating - MarketScreener
PTC Projects Confidence In Sephience Launch With Royalty Buyback - insights.citeline.com
Earnings call transcript: PTC Therapeutics beats Q2 2025 EPS expectations By Investing.com - Investing.com Nigeria
Morgan Stanley Raises Price Target on PTC Therapeutics to $76 From $70, Keeps Overweight Rating - MarketScreener
Ptc Therapeutics 2025 Q2 Earnings Strong Performance as Net Income Surges 34.6% - AInvest
PTC Therapeutics and Evolent Health Receive Bullish Sentiments from Analysts - AInvest
PTC Therapeutics: A Strategic Pivot to Sephience and the Path to Sustained Growth - AInvest
PTC Therapeutics Q2 Loss Narrows, Revenue Declines; Sets Full-Year Revenue Guidance - 富途牛牛
PTC Therapeutics Inc (PTCT) Q2 2025 Earnings Call Highlights: St - GuruFocus
PTC Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
PTC Therapeutics Reports Q2 2025 Financial Results - TipRanks
PTC Therapeutics Q2 2025 Earnings Preview - MSN
PTC Therapeutics: Q2 Earnings Snapshot - Chron
PTC Therapeutics: Balancing Optimism and Uncertainty Amidst New Product Launches and Regulatory Decisions - TipRanks
PTC Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
PTC Therapeutics (PTCT): A Strategic Assessment of Growth Catalysts and Profitability Potential Post-Sephience Approval - AInvest
PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results - Citizen Tribune
Uniqure N.V. shares rise 1.04% after-hours following PTC Therapeutics' positive Q2 earnings report. - AInvest
PTC Therapeutics (PTCT) Reports Q2 Earnings: What Key Metrics Have to Say - Yahoo Finance
PTC Therapeutics (PTCT) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
PTC Therapeutics reports Q2 EPS (83c), consensus ($1.06) - TipRanks
PTC THERAPEUTICS Earnings Results: $PTCT Reports Quarterly Earnings - Quiver Quantitative
PTC Therapeutics Inc Surpasses Revenue Estimates with $179 Million in Q2 2025; Sephience Launch Marks Strategic Milestone - GuruFocus
PTC Therapeutics earnings beat by $0.23, revenue topped estimates - Investing.com Canada
PTC Therapeutics: Pioneering Rare Disease Innovation with a Diversified Pipeline and Strategic Growth Catalysts - AInvest
JPMorgan raises PTC Therapeutics stock price target to $68 on Sephience demand - Investing.com Canada
1.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):